Saltar al contenido
Merck

Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic chondrodysplasia-type Grebe.

European journal of human genetics : EJHG (2013-10-17)
Luitgard M Graul-Neumann, Alexandra Deichsel, Ulrike Wille, Naseebullah Kakar, Randi Koll, Christian Bassir, Jamil Ahmad, Valerie Cormier-Daire, Stefan Mundlos, Christian Kubisch, Guntram Borck, Eva Klopocki, Thomas D Mueller, Sandra C Doelken, Petra Seemann
RESUMEN

Acromesomelic chondrodysplasias (ACDs) are characterized by disproportionate shortening of the appendicular skeleton, predominantly affecting the middle (forearms and forelegs) and distal segments (hands and feet). Here, we present two consanguineous families with missense (c.157T>C, p.(C53R)) or nonsense (c.657G>A, p.(W219*)) mutations in BMPR1B. Homozygous affected individuals show clinical and radiographic findings consistent with ACD-type Grebe. Functional analysis of the missense mutation C53R revealed that the mutated receptor was partially located at the cell membrane. In contrast to the wild-type receptor, C53R mutation hindered the activation of the receptor by its ligand GDF5, as shown by reporter gene assay. Further, overexpression of the C53R mutation in an in vitro chondrogenesis assay showed no effect on cell differentiation, indicating a loss of function. The nonsense mutation (c.657G>A, p.(W219*)) introduces a premature stop codon, which is predicted to be subject to nonsense-mediated mRNA decay, causing reduced protein translation of the mutant allele. A loss-of-function effect of both mutations causing recessive ACD-type Grebe is further supported by the mild brachydactyly or even non-penetrance of these mutations observed in the heterozygous parents. In contrast, dominant-negative BMPR1B mutations described previously are associated with autosomal-dominant brachydactyly-type A2.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Guanidina hydrochloride, for molecular biology, ≥99%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Guanidina hydrochloride, ≥98%
Sigma-Aldrich
L-Glutamina, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Guanidina hydrochloride, organic base and chaeotropic agent, ≥99% (titration)
Sigma-Aldrich
L-Glutamina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Anti-HA antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAFC
L-Glutamina
SAFC
Guanidina hydrochloride
Sigma-Aldrich
Guanidine hydrochloride solution, Colorless liquid, 7.8 - 8.3 M, pH- 4.5 - 5.5
Sigma-Aldrich
L-(−)-Glucose, ≥99%
Sigma-Aldrich
L-Glutamina, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Guanidine hydrochloride solution, BioUltra, ~8 M in H2O
Sigma-Aldrich
Guanidina hydrochloride, ≥99.0% (AT)
Sigma-Aldrich
Guanidina hydrochloride, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Guanidina hydrochloride, anhydrous, free-flowing, Redi-Dri, ≥99%
Sigma-Aldrich
L-Glutamina
Sigma-Aldrich
L-Glutamina, γ-irradiated, BioXtra, suitable for cell culture
Supelco
L-Glutamina, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Glutamina, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland